← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Nigerian Institute Of Medical Research
Lagos
$1,704,518
Total funding
3
Grants
Funding over time
peak $498K · FY2013–25$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
CDC$997,821 · 1
NIH$706,697 · 2
By mechanism
U01$997,821 · 1
K43$706,697 · 2
Investigators at Nigerian Institute Of Medical Research
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy$497,957
U01 · FY2013 · GH
GH12-008, NIGERIA, RESEARCH: HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy$494,864
U01 · FY2015 · GH
Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians$95,208
K43 · FY2024 · TW
Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians$93,972
K43 · FY2023 · TW
Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians$93,106
K43 · FY2021 · TW
Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians$91,601
K43 · FY2022 · TW
Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians$88,462
K43 · FY2025 · TW
Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa$65,447
K43 · FY2024 · TW
Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa$65,433
K43 · FY2023 · TW
Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa$64,980
K43 · FY2025 · TW
Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa$48,488
K43 · FY2024 · TW
HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy$5,000
U01 · FY2014 · GH